D.E. Shaw & Co Portfolio holdings
D. E. Shaw & Co., L.P., founded in 1988 by David E. Shaw, a former Columbia University computer science professor, is a New York City-based global investment management firm renowned for pioneering quantitative investing, managing over $70 billion in assets as of late 2024. Starting with $28 million from Paloma Partners and private investors, the firm employs sophisticated mathematical models and proprietary algorithms—initially developed by a team of scientists and programmers—to exploit market anomalies across public and private markets, including equities, fixed income, and alternatives. Headquartered above a Greenwich Village bookstore in its early days, it now boasts over 2,500 employees across offices in North America, Europe, and Asia, led by a seven-member Executive Committee since Shaw stepped back in 2001 to focus on D. E. Shaw Research. Despite setbacks like the 1998 Russia debt crisis and the 2008 financial downturn, the firm has maintained a reputation for analytical rigor, risk management, and innovation, balancing its computational roots with discretionary strategies.
Top Buys
| 1 |
Qualcomm
QCOM
|
+$555M |
| 2 |
Marathon Petroleum
MPC
|
+$538M |
| 3 |
Ford
F
|
+$529M |
| 4 |
Walmart
WMT
|
+$508M |
| 5 |
Apple
AAPL
|
+$499M |
Top Sells
| 1 |
Microsoft
MSFT
|
+$716M |
| 2 |
Merck
MRK
|
+$498M |
| 3 |
Meta Platforms (Facebook)
META
|
+$425M |
| 4 |
McDonald's
MCD
|
+$369M |
| 5 |
Wells Fargo
WFC
|
+$362M |
Sector Composition
| 1 | Technology | 20.88% |
| 2 | Consumer Discretionary | 13.12% |
| 3 | Healthcare | 9.93% |
| 4 | Communication Services | 9.58% |
| 5 | Financials | 7.83% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
2951
The Joint Corp
JYNT
$157M
| $288K | ﹤0.01% |
3,433
-52,217
| -94% | -$4.38M |
|
2952
LENSAR
LNSR
$145M
| $288K | ﹤0.01% |
33,306
-6,589
| -17% | -$57K |
|
2953
Nicolet Bankshares
NIC
$2.01B
| $288K | ﹤0.01% |
4,088
-3,405
| -45% | -$240K |
|
|
DLCAU
2954
DELISTED
Deep Lake Capital Acquisition Corp. Unit
DLCAU
| $288K | ﹤0.01% |
28,467
+11,767
| +70% | +$119K |
|
2955
Pulse Biosciences
PLSE
$1.02B
| $287K | ﹤0.01% |
+17,528
| New | +$287K |
|
2956
Smart Sand
SND
$75.5M
| $287K | ﹤0.01% |
+86,169
| New | +$287K |
|
2957
Albemarle
ALB
$8.83B
| $286K | ﹤0.01% |
1,696
-49,111
| -97% | -$8.28M |
|
2958
Idexx Laboratories
IDXX
$51.6B
| $285K | ﹤0.01% |
452
-636
| -58% | -$401K |
|
2959
LeMaitre Vascular
LMAT
$2.13B
| $282K | ﹤0.01% |
4,619
-14,012
| -75% | -$855K |
|
2960
HUTCHMED
HCM
$2.81B
| $281K | ﹤0.01% |
7,162
-19,408
| -73% | -$761K |
|
2961
Liberty Latin America Class A
LILA
$1.53B
| $278K | ﹤0.01% |
+20,036
| New | +$278K |
|
|
NOAH
2962
Noah Holdings
NOAH
$793M
| $278K | ﹤0.01% |
+5,899
| New | +$278K |
|
|
NBSE
2963
DELISTED
NeuBase Therapeutics, Inc. Common Stock
NBSE
| $278K | ﹤0.01% |
2,899
-1,913
| -40% | -$183K |
|
|
AKYA
2964
DELISTED
Akoya BioSciences
AKYA
| $277K | ﹤0.01% |
+14,309
| New | +$277K |
|
|
CGAU
2965
Centerra Gold
CGAU
$1.86B
| $276K | ﹤0.01% |
+36,300
| New | +$276K |
|
2966
GT Biopharma
GTBP
$2.65M
| $275K | ﹤0.01% |
+591
| New | +$275K |
|
|
CRXT
2967
DELISTED
Clarus Therapeutics Holdings, Inc. Common Stock
CRXT
| $273K | ﹤0.01% |
+27,118
| New | +$273K |
|
2968
Celanese
CE
$5.13B
| $271K | ﹤0.01% |
1,790
-84,471
| -98% | -$12.8M |
|
2969
BRF SA
BRFS
$6.09B
| $269K | ﹤0.01% |
49,143
-1,729,329
| -97% | -$9.47M |
|
|
CKPT
2970
DELISTED
Checkpoint Therapeutics
CKPT
| $268K | ﹤0.01% |
+9,075
| New | +$268K |
|
2971
eHealth
EHTH
$124M
| $268K | ﹤0.01% |
4,590
-12,553
| -73% | -$733K |
|
2972
Arq
ARQ
$301M
| $267K | ﹤0.01% |
36,043
-420
| -1% | -$3.11K |
|
2973
AquaBounty Technologies
AQB
$4.46M
| $266K | ﹤0.01% |
+2,483
| New | +$266K |
|
2974
Pricesmart
PSMT
$3.63B
| $265K | ﹤0.01% |
2,909
-21,803
| -88% | -$1.99M |
|
|
LMACU
2975
DELISTED
Liberty Media Acquisition Corporation Unit
LMACU
| $265K | ﹤0.01% |
25,000
| – | – |
|